Other languages Iconovo AB

Equities

ICO

SE0010868943

Market Closed - Nasdaq Stockholm Other stock markets 17:00:00 25/06/2024 BST			5-day change	1st Jan Change
9.56 ^SEK	+0.63%		-4.88%	-17.23%

05-15	Iconovo AB Files Patent Application for Inhaled GLP-1 Products and Initiates Development of New Obesity Treatments	CI
05-06	Sweden's Iconovo to Receive Chinese Patent for ICOres Inhaler	MT

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Iconovo AB Files Patent Application for Inhaled GLP-1 Products and Initiates Development of New Obesity Treatments	05-15
Sweden's Iconovo to Receive Chinese Patent for ICOres Inhaler	05-06
Iconovo AB Receives Patent Protection for Icores in China	05-06
Iconovo AB Reports Earnings Results for the First Quarter Ended March 31, 2024	04-25
Iconovo AB and Affilogic to Present Positive Data from a Feasibility Study on Nanofitins in ICOone	03-11
Iconovo AB Reports Earnings Results for the Full Year Ended December 31, 2023	02-15
Iconovo AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-15
Iconovo AB Signs Additional Contract with Kiox Pharma for the Development of A New Inhalable Treatment for Interstitial Lung Disease	02-07
Iconovo AB Launches Improved Versions of Nasal ICOone Inhalers	02-06
Iconovo Receives Order from Top-10 Pharma Company for Evaluation of Multi-Dose Inhaler	02-01
Arcede Pharma and Iconovo AB Takes the Next Step in the Development of a New Treatment for COPD	11-16
Iconovo AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	27/10/23
Iconovo AB Completes Enrollment in Phase I Clinical Trial of Inhaled Oxytocin in ICOone	26/09/23
Iconovo AB Receives US Patent for Ioccap That Strengthens the Offering for More Customer Collaborations	19/09/23
Iconovo AB Launches Outreach Phase in Structured Process for Out-Licensing of ICOpre	13/09/23
Iconovo AB Provides Earnings Guidance for the Years 2024, 2025, 2026 and 2027	23/08/23
Iconovo to Launch Pharmacokinetic Study for Inhalable Treatment Under Kiox Pharma Partnership	17/08/23
Iconovo AB Receives Additional Development Contract from Kiox Pharma for New Inhalable Treatment Against Rare Disease	17/08/23
Iconovo AB, Provides Earnings Guidance for 2024 and 2025	16/08/23
Iconovo AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/07/23

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Iconovo AB

Equities

ICO

SE0010868943

Other languages

Filters